BACKGROUND: We aimed to evaluate the safety and efficacy of methylene blue dye (MBD) for sentinel lymph node (SLN) mapping in breast cancer. METHODS: A total of 398 patients undergoing 401 SLN biopsy procedures with MBD were retrospectively reviewed and divided into 3 groups based on dye concentration and location of dye injection. Technical success and complication rates were compared. RESULTS: Overall technical success of SLN biopsy was 99.7%. Technical success of SLN mapping with MBD was lowest in the group receiving full strength dye in a peritumoral location (74%) and highest in the group that received very dilute MBD (1.25 mg/mL) in the subareolar location (92%, P = .004). The complication rate was highest in the first group (21%) and lowest in the latter (2%, P = .0003). CONCLUSIONS: Dilute MBD (1.25 mg/mL) successfully maps SLNs with very few complications.
BACKGROUND: We aimed to evaluate the safety and efficacy of methylene blue dye (MBD) for sentinel lymph node (SLN) mapping in breast cancer. METHODS: A total of 398 patients undergoing 401 SLN biopsy procedures with MBD were retrospectively reviewed and divided into 3 groups based on dye concentration and location of dye injection. Technical success and complication rates were compared. RESULTS: Overall technical success of SLN biopsy was 99.7%. Technical success of SLN mapping with MBD was lowest in the group receiving full strength dye in a peritumoral location (74%) and highest in the group that received very dilute MBD (1.25 mg/mL) in the subareolar location (92%, P = .004). The complication rate was highest in the first group (21%) and lowest in the latter (2%, P = .0003). CONCLUSIONS: Dilute MBD (1.25 mg/mL) successfully maps SLNs with very few complications.
Authors: Amy C Degnim; Alyssa D Throckmorton; Sarah Y Boostrom; Judy C Boughey; Andrea Holifield; Larry M Baddour; Tanya L Hoskin Journal: Ann Surg Oncol Date: 2012-06-26 Impact factor: 5.344
Authors: Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath Journal: Nucl Med Biol Date: 2015-12-03 Impact factor: 2.408
Authors: Floris P R Verbeek; Susan L Troyan; J Sven D Mieog; Gerrit-Jan Liefers; Lorissa A Moffitt; Mireille Rosenberg; Judith Hirshfield-Bartek; Sylvain Gioux; Cornelis J H van de Velde; Alexander L Vahrmeijer; John V Frangioni Journal: Breast Cancer Res Treat Date: 2013-12-13 Impact factor: 4.872
Authors: Ted A James; Alex R Coffman; Anees B Chagpar; Judy C Boughey; V Suzanne Klimberg; Monica Morrow; Armando E Giuliano; Seth P Harlow Journal: Ann Surg Oncol Date: 2016-07-21 Impact factor: 5.344
Authors: Susan L Troyan; Vida Kianzad; Summer L Gibbs-Strauss; Sylvain Gioux; Aya Matsui; Rafiou Oketokoun; Long Ngo; Ali Khamene; Fred Azar; John V Frangioni Journal: Ann Surg Oncol Date: 2009-07-07 Impact factor: 5.344
Authors: Sreekar Devarakonda; Shawn Sam Thomas; Supriya Sen; Varghese Thomas; Reka Karuppusami; Anish Jacob Cherian; Pooja Ramakant; Deepak Thomas Abraham; Paul Mazhuvanchary Jacob Journal: Indian J Surg Oncol Date: 2021-01-16